OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Drug Safety is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)	38
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study	35
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada	28
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions	26
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study	18
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community	16
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana	15
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database	15
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging	13
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend	13
Corrigendum	13
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey	12
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis	12
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study	11
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study	11
Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience	10
Increasing patient involvement through self-administration of medication	10
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review	9
The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey	8
The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology	8
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences	8
Impact of risk communication on patient’s safety during the pandemic	8
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction	7
Artificial intelligence in drug development: reshaping the therapeutic landscape	7
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward	6

Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic	6
Flow rate accuracy of infusion devices within healthcare settings: a systematic review	6
A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States	6
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system	5
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations	5
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database	5
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System	4
Is there a risk of esketamine misuse in clinical practice?	4
Seizure following in-office lidocaine administration: a case report on local anesthetic systemic toxicity	4
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers	4
The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries	4
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database	4
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-met	4
Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization	4
Drug safety of frequently used drugs and substances for self-medication in COVID-19	4
Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial	4
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries	4